Project Grant R44CA254613

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...

This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...

This Project Grant award from the National Cancer Institute, funded under the Cancer Treatment Research program (CFDA 93.395), is focused on developing peptide drug conjugates to treat triple negative breast cancer (TNBC). The goal is to create novel peptide-based drug delivery systems to improve the efficacy of chemotherapies for this aggressive form of breast cancer. The $530,358 award to Molecular Theranostics LLC will support two key objectives: 1) synthesizing and characterizing a peptide...

The National Cancer Institute (NCI) awarded a $898,497 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Radiopharmaceutical Imaging and Dosimetry, LLC to develop a cloud-based, customer-responsive dosimetry tool for alpha-particle emitting radiopharmaceutical therapies. The key objectives are to: 1) establish a library of microscale S-values and apportionment factors for dose-limiting tissues, 2) implement a macro-to-micro dosimetry methodology to enable...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Cancer Targeted Technology LLC to develop and validate a novel PSMA-targeted small molecule prodrug called CTT2274 for the treatment of advanced prostate cancer. The key product being developed under this award is CTT2274, which utilizes a unique prodrug delivery mechanism to concentrate the potent tubulin disruptor monomethyl auristatin E (MMAE) selectively within...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,024,967.00 to Celdara Medical, LLC for the development of CM-HZ01, a novel non-alpha-IL2 therapeutic for the treatment of metastatic melanoma. The project aims to advance CM-HZ01 through Investigational New Drug (IND) filing for clinical testing in metastatic melanoma patients, a condition with limited effective treatment options. The funding supports research to engineer a selective...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Oncotab, Inc. to develop optimized targeted radiotherapy for pancreatic ductal adenocarcinoma (PDAC). The project aims to conduct a structured design of experiments to evaluate two targeting agents - a humanized antibody (HTAB004) and a tandem single-chain variable fragment (scFv) - labeled with alpha and beta particle-emitting radioisotopes. The goal is to identify the...

The Project Grant award R01CA287491, totaling $720,416, was provided by the National Cancer Institute (NCI) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The award aims to develop a novel "theranostic" (therapeutic and diagnostic) approach using chimeric antigen receptor (CAR) T-cell therapy for the treatment of neuroendocrine prostate cancer (NEPC). The key products and services to be delivered include: Evaluating the therapeutic efficacy of...

This $692,072 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund the development of a novel theranostic platform using PSMA-targeted poly(amidoamine) (PAMAM) dendrimers for the management of prostate cancer. The key products to be delivered include: PSMA-targeted theranostic agents that enable highly specific targeting, quantitative PET/CT imaging for patient selection, and delivery of potent antimitotic agents....

The U.S. National Cancer Institute has awarded a $1,003,173 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Radiopharmaceutical Imaging and Dosimetry, LLC, a for-profit company based in Baltimore, Maryland. The grant is for the development of a prototype web/cloud-based quantitative SPECT reconstruction software system that can be used for clinical trials and dosimetry of radiopharmaceutical cancer therapies, particularly those utilizing alpha-emitting radionuclides. The key...